Skip to main content

Table 2 Responses based on IMWG criteria

From: A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial

Variable Pomalidomide plus dexamethasone (N = 36)
Response rate, n (%)
 Overall response 15 (41.7)
  Complete response 1 (2.8)
  Very good partial response 0
  Partial response 14 (38.9)
 Stable disease 16 (44.4)
 Progressive disease 5 (13.9)
 Not evaluable 0
Time to response, median (range), months 1.9 (0.9–5.5)
Duration of response, median (range), months Not reached (1.9–11.1)
  1. IMWG International Myeloma Working Group